FDA kicks 'moderate' out of ER/LA opioid pain indication
This article was originally published in Scrip
Executive Summary
US regulators on 10 September told makers of extended-release (ER) and long-acting (LA) opioids, such as morphine, oxycodone and fentanyl, they must add new warnings to the labeling of their products and revise the indications of the medicines as part of an effort to help curb the abuse and misuse of the drugs.